• Represents the company as a medical expert in interactions with regulatory and oversight agencies worldwide, such as the FDA.• Provides clinical consultation to customers worldwide relative to the company's diagnostic products and clinical results• Assist with developing and delivering relevant information, educational material, presentations, and seminars useful and appropriate for clinicians• Represents the Company in the key global industry and medical associations, initiatives, formulation of clinical diagnostic guidelines• Conducts literature reviews as needed to support medical affairs related activities and decisions• Provides clinical assessment, in consultation with external 3rd parties as needed, relative to risk analysis of product performance or events• Supports the development and preparation of strategies, information and materials for effective product positioning

Bratton LabWorx accelerates the growth of laboratories by deploying practical strategies for aligning operational and regulatory excellence with radical vision. We focus on three strategic pillars; (1) regulatory compliance, (2) operational efficiency, and (3) vision. Clinical laboratories, regardless of ownership, geography, capital, or test menu cannot succeed in the absence of regulatory compliance. Our consultants have experience and expertise in CLIA, CAP, CLIP, COLA, and ISO accreditation. In the current economy of laboratory medicine, which is heavily dependent on insurance payer reimbursement or, in some areas, direct to consumer testing, operational efficiency is critical for sustainability. Our consultants can observe the workflows of any clinical lab and develop practical strategies that can be implemented immediately to improve operational efficiency. The powerful combination of regulatory compliance and operational efficiency drive quality results, patient safety, and customer satisfaction. Those results, however, are of limited consequence if the laboratory cannot sustain volume or initiate growth. Bratton LabWorx consultants strive to stay on the bleeding edge of laboratory diagnostics and can develop strategic initiatives that align with the values of the laboratory and business. Exceptional execution of this strategic framework drives the achievement of the Bratton LabWorx mission.If you need results fast – we can move faster! If you own/operate a smaller lab, there’s a good chance that your needs may get lost in the shuffle of bigger clients at a large firm. Conversely, every client is a VIP to Bratton LabWorx. We have found that there is no “one size fits all” approach that works effectively. We provide a specialized service, bespoke to the needs of individual customers and/or clients. www.brattonlabworx.com – capabilities and testimonials

• Functioned as a technical and scientific Transplant subject matter expert to support the account management team in meeting revenue, profit and penetration / market share goals.• Worked with North America Sales Director of Transplant to create a territory plan identifying renewal and new business opportunities. • Led team of 6, directing the design and infrastructure, instrumentation, and IT and quality system integration in collaboration with stakeholders to build a clinical laboratory in alignment with the operational needs for post-renal transplant monitoring• Established and implemented the Quality Management System, oversaw the build of the informatics system, and developed the initial budget, influencing the growth of the new department• Coordinated with local, state, and federal agencies to implement regulatory standards within the new business, ensuring overall compliance.

The Transplant Center at Mercy Medical Center – Des Moines was established in 1986 and is one of the most experienced programs in central Iowa, producing outstanding results in the field of transplantation.Mercy Transplant Center combines compassionate medical care with the latest in surgery and technology. Each transplant patient receives one-on-one care during each stage – from pre-transplant evaluation to post-transplant follow-up.

• Oversee a national team of 150+ employees across the US to manage the startup operations of 4 laboratories through strategic planning efforts, ensuring business continuity and growth following the COVID-19 pandemic• Integral in performing 500 tests annually in 1 small lab in Philadelphia, achieving CAP accreditation by the nationally recognized regulatory body for clinical labs in 2019• Influenced a massive expansion during the COVID-19 pandemic by building an additional 3 labs in Georgia, California, and New York in 1 year, expanding from 500 to 750K tests between Q3 2020 and Q2 2021• Appointed as a member of the Scientific Advisory Board, collaborating with the Chief Medical Officer to remain up-to-date on the most recent scientific journal publications and leverage the scientific knowledge and industry insight for developing the scientific strategy, driving external innovation of the company

• Functioned as a technical and scientific Transplant subject matter expert to support the account management team in meeting revenue, profit and penetration / market share goals. • Worked with North America Sales Director of Transplant to create a territory plan identifying renewal and new business opportunities. • Led team of 6, directing the design and infrastructure, instrumentation, and IT and quality system integration in collaboration with stakeholders to build a clinical laboratory in alignment with the operational needs for post-renal transplant monitoring • Established and implemented the Quality Management System, oversaw the build of the informatics system, and developed the initial budget, influencing the growth of the new department • Coordinated with local, state, and federal agencies to implement regulatory standards within the new business, ensuring overall compliance.

• Managed a team of 6 members while maintaining a capital and operations budget of $1M annually to develop the transplant center through high-end and innovative transplant diagnostics, positioning the center as a nationally recognized program• Optimized the testing protocols and implemented a strategy for transplant and operating room management to effectively match recipients with donors and enhance the operations, growing the lab revenues by $7M annually• Streamlined the operations of the department to minimize lab staff workflow, boosting morale and retention as well as reducing physician and patient wait time between the time of donor offer and the operating room procedures by 4 hours, leading to a decrease in cold ischemic time of the allografts to facilitate improved patient outcomes• Invited to present at various national and international meetings and events, earning the Junior Faculty Clinical Case Dilemmas Best Presentation Award and Best Young Investigator Award from the International Society of Heart and Lung Transplantation (ISHLT) in 2018

• Led an Associate Director and Laboratory Manager, directing the design and infrastructure, instrumentation, and IT and quality system integration in collaboration with stakeholders to build a clinical laboratory in alignment with the operational needs for clinical trial participant testing, enhancing the safety of adverse drug events and pharmacokinetics and pharmacodynamics monitoring• Hired a team of 10 new staff members, established and implemented the Quality Management System, oversaw the build of the informatics system, and developed the budget for 2022, influencing the growth of the new department• Coordinated with local, state, and federal agencies to implement regulatory standards within the new business, ensuring overall compliance

About Usg6 GENOMICS+ is a comprehensive, diagnostics company that is paving the way for the advancement of personalized medicine. Committed to providing high-quality pharmacogenetic testing, g6 GENOMICS+ delivers precise, actionable results to healthcare providers to assist in the management of their patients’ therapeutic needs.Our MissionBecause we are all different… At g6 GENOMICS+, we recognize the importance of personalized medicine. Our mission is to provide value and support to healthcare professionals while making a difference in the lives of their patients. We deliver an unrivaled, customer focused experience that streamlines our unique approach to individualized medicine. By employing the latest technology available and offering clinical support from experts in the fields of pharmacogenetics and clinical pharmacology, g6 GENOMICS+ stays in the forefront of genetic testing, helping to meet the needs of both patient and clinician.

The Histocompatibility Laboratory at UHN supports the largest solid organ and bone marrow transplant programs in Canada providing testing for transplant programs at the Hospital for Sick Children, St. Michael's Hospital, Toronto General Hospital, and Princess Margaret Cancer Centre.​The laboratory is accredited with the Ontario Laboratory Association and the American Society for Histocompatibility and Immunogenetics and utilizes a diverse array of tests and technologies.My responsibilities include the oversight of quality assurance/quality control practices in the Laboratory; development and validation of new testing technologies and platforms; development and validation of standard processes for workflow in the Lab, and between the lab and stakeholders; review of testing and creation/finalization of all solid organ, bone marrow, disease association and research based reports. Consultation with clinical programs where specialized testing/interpretation is required, continuing education of technologies; development or educational platforms and provision of continuing education of clinical trainees. On-call availability to clinical programs and technologists; interaction with stakeholder clinical programs and services.

A two-year histocompatibility and transplant immunology (HLA) fellowship focusing on donor screening, methodology, and clinical correlation of testing. The program covers not only solid organ but also bone marrow/stem cell transplantation, allele and haplotype frequency determinations, and molecular testing. Training in laboratory management and information systems is included as well as scholarly activity in the form of various research projects.Fellows are expected to successfully pass the American Board of Histocompatibility and Immunogenetics (ABHI) board examination for histocompatibility directors after completion of the two-year fellowship program.

The goal of the postdoctoral program in clinical chemistry at Emory University is to educate and train Ph.D. scientists for careers in clinical chemistry. Through unique partnerships in the Atlanta area, this program is designed to prepare trainees for academic, clinical service, and industry positions. The duration of the program is a minimum of two years. The program is structured such that, during the first few months, the fellow is prepared for clinical service through didactic teachings and rotations through areas of the clinical laboratory. Following the first few months, the fellow becomes active in clinical service by assisting with clinical projects and on-call responsibilities for the laboratory. Trainees become involved in research projects during this time. Lastly, fellows must pass a written examination based on all aspects of clinical chemistry and on fundamental knowledge in biochemistry and other related disciplines to become certified by the American Board of Clinical Chemistry (ABCC). Certification by the ABCC satisfies the personnel requirements of CLIA '88 regulations to serve as the director of a high complexity clinical laboratory and clinical consultant in laboratory medicine.

Dissertation: "Suppression of calcineurin signaling and pgc-1alpha expression during the chronic skeletal muscle atrophy associated with diabetes mellitus : implications for muscle function."Skeletal muscle atrophy frequently indicates a poor prognosis for patients with systemic pathologies, including diabetes mellitus (DM). These patients demonstrate reduced muscle size as well as decreased strength and endurance, indicating that a link exists between muscle size and functional capacity in these conditions. PGC-1alpha is a transcriptional coactivator that controls energy homeostasis through regulation of glucose and oxidative metabolism. Both PGC-1alpha expression and oxidative capacity are decreased in skeletal muscle of diabetic patients and animals undergoing atrophy, suggesting that PGC-1alpha participates in the regulation of muscle mass. This dissertation focuses on elucidating the mechanisms that regulate PGC-1alpha expression in vivo in a model of DM as well as the potential physiological effects of PGC-1alpha downregulation.